L
Lee S. Rosen
Researcher at University of California, Los Angeles
Publications - 226
Citations - 17049
Lee S. Rosen is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Cancer & Tolerability. The author has an hindex of 50, co-authored 209 publications receiving 16056 citations. Previous affiliations of Lee S. Rosen include University of Michigan & UCLA Medical Center.
Papers
More filters
Journal ArticleDOI
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Leonard B. Saltz,John Cox,Charles D. Blanke,Lee S. Rosen,Louis Fehrenbacher,Malcolm J. Moore,Jean A. Maroun,Stephen P. Ackland,Paula K. Locker,Nicoletta Pirotta,Gary Elfring,Langdon L. Miller +11 more
TL;DR: In this paper, the authors compared a combination of irinotecan, fluorouracil, and leucovorin with bolus doses of leucocil as first-line therapy for metastatic colorectal cancer.
Journal ArticleDOI
Colorectal cancer screening: Clinical guidelines and rationale
Sidney J. Winawer,Robert H. Fletcher,L Miller,F. Godlee,M. H. Stolar,Cynthia D. Mulrow,Steven H. Woolf,SN Glick,Theodore G. Ganiats,John H. Bond,Lee S. Rosen,J. G. Zapka,S. J. Olsen,Francis M. Giardiello,J. E. Sisk,R. Van Antwerp,C. Brown-Davis,D. A. Marciniak,Robert J. Mayer +18 more
TL;DR: This guideline report presents the panel’s recommendations with respect to screening and surveillance in people at average risk for CRC and those at increased risk because of a family history of CRC or genetic syndromes or a personal history of adenomatous polyps, inflammatory bowel disease, or curative-intent resection of CRC.
Journal Article
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Lee S. Rosen,David Gordon,Mary Kaminski,Anthony Howell,Andrew R. Belch,John R. Mackey,J. Apffelstaedt,Mohamed Hussein,Robert E. Coleman,Dirk J. Reitsma,John J. Seaman,Bee Lian Chen,Yvonne Ambros +12 more
TL;DR: Zoledronic acid (4 mg) via 15-minute intravenous infusion was as effective and well tolerated as 90 mg of pamidronate in the treatment of osteolytic and mixed bone metastases/lesions in patients with advanced breast cancer or multiple myeloma.
Journal ArticleDOI
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Lee S. Rosen,David Gordon,Mary Kaminski,Anthony Howell,Andrew R. Belch,John R. Mackey,J. Apffelstaedt,Mohamad A. Hussein,Robert E. Coleman,Dirk J. Reitsma,Bee-Lian Chen,John J. Seaman +11 more
TL;DR: In this article, the authors compared the long-term safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma.
Journal ArticleDOI
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Lee S. Rosen,David Gordon,Simon Tchekmedyian,Ronald Yanagihara,Vera Hirsh,Maciej Krzakowski,Marek Pawlicki,Paul de Souza,Ming Zheng,Gladys Urbanowitz,Dirk J. Reitsma,John J. Seaman +11 more
TL;DR: Zoledronic acid (4 mg infused over 15 minutes) is the first bisphosphonate to reduce skeletal complications in patients with bone metastases from solid tumors other than breast and prostate cancer.